Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel

Anticancer Research

Volumn 27, Issue 3 B, 2007, Pages 1645-1651

  Polyzos, Aristides ^a   Kosmas, Christos ^b   Tsavaris, Nikolas ^a   Toufexi, Helen ^a   Lagadas, Antonios ^a   Gogas, Helen ^a   Giannakopoulos, Kostas ^a   Kouraklis, Gregory ^a   Griniatsos, John ^a   Felekouras, Evagelos ^a   Tsigris, Christos ^a   Nikiteas, Nikolas ^a   Papadopoulos, Othon ^a   Giannopoulos, Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

Author keywords

Cisplatin; Ifosfamide; Ovarian cancer; Paclitaxel; Salvage treatment

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PACLITAXEL; PLATINUM COMPLEX;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; OVARY CANCER; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RENAL PROTECTION; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IFOSFAMIDE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 34249281328     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
2. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B and Pecorelli S: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708, 2000.
3. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr: Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389-393, 1991.
4. Eisenhauer EA, Vermorken JB and Van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8: 963-968, 1997.
5. Sutton GP, Blessing JA, Homesley HD, Berman ML and Malfetano J: Phase II trial of ifosmamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 7: 1672-1676, 1989.
6. Markman H, Hakes TH, Reichman B, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Pizzuto F and Hoskins W: Ifosmamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 10: 243-248, 1992.
7. Sorensen P, Pfeiffer P and Bertelsen K: A phase II trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 56: 75-78, 1995.
8. Dorval T, Soussain C, Beuzeboc P, Garcia-Giralt E, Jouve M, Livartowski A, Mosseri V, Palangie T, Scholl S, Sastre X and Pouillart P: Ifosfamide seven-day infusion for recurrent and cisplatin resistant ovarian cancer. J Infus Chemother 6: 47-49, 1996.
9. Markman M, Kennedy A, Sutton G, Hurteau J, Webster K, Peterson G, Kulp B and Belinson J: Phase II trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 70: 272-274, 1998.
10. Scarfone G, Villa A, Parazzini F, Sciatta C, Polverino G and Bolis G: A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Tumori 85: 217-219, 1999.
11. Polyzos A, Tsavaris N, Kosmas C, Petrikos G, Giannikos L, Kalahanis N, Papadopoulos O, Christodoulou K, Giannakopoulos K, Veslemes M and Katsilambros N: Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide. J Chemother 11: 144-149, 1999.
12. Vanhoefer U, Schleucher N, Klaassen U, Seeber S and Harstrick A: Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic. Semin Oncol 27(Suppl 1): 8-13, 2000.
13. Kosmas C, Tsavaris NB, Polyzos A, Malamos NA, Katsikas M and Antonopoulos MJ: Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. Br J Cancer 82: 300-307, 2000.
14. Kosmas C, Polyzos A, Tsavaris N, Katsikas M, Giannikos L, Kalahanis N, Christodoulou K, Giannakopoulos K and Katsilambros N: Outpatient Taxol®, ifosfamide and cisplatin (TIP) as salvage chemotherapy in pretreated patients with ovarian cancer. Proc Am Soc Clin Oncol 17: 366a (abst 1414), 1998.
15. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
16. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
17. Joly F, Bourgeois H, Floquet A, Chinet-Charrot P, Meyer F, Lebrun D, Hamond K, Leroy C and Heron JF: Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer. Int J Gynecol Cancer 16(1): 77-82, 2006.
18. Bourgeois H, Joly F, Pujade-Lauraine E, Cure H, Guastalla JP, Ferru A, Chabrun V, Chieze S and Tourani JM: Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients. Am J Clin Oncol 29(4): 399-404, 2006.
19. Bauz M, Fazeny-Doerner B, Hudec M, Sevelda P, Salzer H and Dittrich C: Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients long-term results of a phase II study. Cancer Invest 24(1): 22-27, 2006.
20. Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F and Reed E: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr 15: 83-88, 1993.
21. Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E and Shulan LN: A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer 82: 561-566, 1998.
22. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR and Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010-2020, 1993.
23. Lind MJ, McGown AT, Hadfield JA, Thatcher N, Crowther D and Fox BW: The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 38: 1835-1840, 1989.
24. Gercel-Taylor C, Scobee JJ and Taylor DD: Effect of chemotherapy on the mutation frequency of ovarian cancer cells at the HPRT locus. Anticancer Res 25: 2113-2117, 2005.
25. Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J and Maher M: Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 22(Suppl 6): 90-96, 1995.
26. Polyzos A, Kosmas C, Toufexi H, Malamos N, Lagadas A, Kosmidis C, Ginopoulos P, Ziras N, Kandilis K and Georgoulias V: Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res 25: 3559-3564, 2005.
27. Aravantinos G, Bafaloukos D, Fountzilas G, Christodoulou C, Papadimitriou C, Pavlidis N, Kalofonos HP, Gogas H, Kosmidis P and Dimopoulos MA: Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 14(7): 1094-1099, 2003.
28. Skarlos DV, Kalofonos HP, Fountzilas G, Dimopoulos MA, Pavlidis N, Razis E, Economopoulos T, Pectasides D, Gogas H, Kosmidis P, Bafaloukos D, Klouvas G, Kyratzis G and Aravantinos G: Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Anticancer Res 25: 3103-3108, 2005.
29. Gallardo D, Calderillo G, Serrano A, Alexander F, Rodriguez G, Perez L, de la Garza J, Orate-Ocana L and Otero J: A phase II study of gemcitabine plus cisplatin in previously untreated advanced ovarian cancer. Anticancer Res 26: 3137-3141, 2006.
30. Papadimitriou CA, Kouroussis C, Moulopoulos LA, Vlahos G, Rodolakis A, Kiamouris C, Diakomanolis E, Gika D, Michals S and Dimopoulos MA: Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer. Cancer 92(7): 1856-1863, 2001.
31. Zylberberg B, Dormont D, Madelenat P and Darai E: First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in stage IIIc ovarian epithelial cancer. Eur J Gynaecol Oncol 25(3): 327-332, 2004.